Atorvastatin in Myeloma

Phase 1

• Conditions: Myeloma

• Registration Number: NCT00164086
• Lead Sponsor: Bayside Health

Brief Summary

The purpose of this trial is to study the effects of a medication already widely used to treat cardiovascular disease and diabetes, in reducing the progression of myeloma.

Detailed Description

Not available

Study Timeline

• Status Verified: 2005-09
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-14
• Last Update Submitted: 2006-10-10
• Last Update Posted: 2006-10-11

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Myeloma in remission

Exclusion Criteria

• Adverse events (AEs) to statin, already on a statin, or contraindication to statin

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

Alfred Hospital; 🇦🇺 Melbourne, Victoria, Australia